Approval · Notice of Compliance 33151 · 2024
JAMP POMALIDOMIDE: Notice of Compliance 33151
Issued May 2, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33151
- Date
- May 2, 2024
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving: Production of the drug substance
- Canadian reference product
- POMALYST (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP POMALIDOMIDE | Not yet assigned | — |
Medicinal ingredients
- POMALIDOMIDE 4 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 1 MG per CAP